baber/WOPTO huggingface dataset:
Patent NZ-549877-A (NZ)
Title: X-ray visible drug delivery device
Inventor: VEENSTRA HARM
IPC: A61K31/565
Filed: 2005-03-14
Abstract: Disclosed is an X-ray visible drug delivery device for subdermal administration of a contraceptive or hormone replacement therapy. The device comprises one compartment consisting of: (i) a thermoplastic polymer core loaded with (a) a contraceptively effective or therapeutically effective amount of desogestrel or 3 ketodesogestrel, and (b) about 4-30% by weight radio-opaque material; and (ii) a non-medicated thermoplastic polymer skin covering the core.
Patent NZ-549930-A (NZ)
Title: Key combination element in key blank and key
Inventor: MARKBREIT DANI
IPC: E05B19/00
Filed: 2005-03-28
Abstract: A key blank including a generally elongate shaft portion defining first and second generally flat oppositely directed side surfaces, joined by edge surfaces, at least one of the first and second side surfaces cuttable to form key cuts that define a key combination surface, and at least one key combination element movably disposed in the elongate shaft portion and adapted for touching a lock combination element disposed in a cylinder lock plug, wherein the at least one key combination element has inherent energy for applying an urging force against the lock combination element. A key formed from the key blank and lock therefore are also disclosed.
Patent NZ-554550-A (NZ)
Title: Stable and filterable enveloped virus formulations
Inventor: CHEN TZER-FEN
IPC: C12N7/02
Filed: 2005-11-04
Abstract: Disclosed is a method for stabilizing an enveloped virus for storage in aqueous solution for six months or longer at a temperature from -4 degrees Celsius to -30 degrees Celsius, comprising preparing an aqueous solution consisting essentially of: the enveloped virus at a concentration of from 106 PFU/mL to 1012PFU/ml; and a non-reducing saccharide, wherein the saccharide is a disaccharide and is present in the solution at a concentration of from 5%(w/v) to 50%(w/v) or a monosaccharide and is present in the solution at a concentration of from 2.5% (w/v) to 25%(w/v); wherein the solution has an osmotic pressure of about 250 mOs or higher; has a pH of from 5 to 10; and contains less than 0.1% (w/v) sodium chloride.
Patent NZ-569389-A (NZ)
Title: Methods of making and using theaflavin, theaflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3,3'-digallate and mixtures thereof
Inventor: ZHAO JIAN
IPC: A23L33/20
Filed: 2002-11-27
Abstract: Disclosed is the use of an isolated mixture of theaflavin, theaflavin-3-gallate, theaflavin-3Æ-gallate and theflavin 3,3Æ-digallate in the manufacture of a composition for treating or preventing hyperlipidemia, coronary heart disease, apoplexy, atherosclerotic cardiovascular disease, diabetes, von WillebrandÆs disease, leukopenia, cerebral infarction, fatty liver, or for reducing low density lipoprotein (LDL) levels.
Patent NZ-573012-A (NZ)
Title: Anchor for casting into concrete with formwork attachement at opposite end to entry to passage of anchor
Inventor: IRELAND BRUCE IAN
IPC: E04C5/12
Filed: 2007-07-16
Abstract: An anchor assembly (10) has an anchor housing in the form of an integral nut body (11), a positioning means in the form of a locating plate (12), a passage means in the form of a tube (13), a tube coupling (14) and an end cap (not shown) to close the end of the tube. The locating plate, in use, is fastened to formwork adjacent or at the end of the assembly opposite the entry to the passage means.
Patent NZ-583696-A (NZ)
Title: Diagnostic substances for optical imaging testing on the basis of nanoparticular formulations
Inventor: BAHNER MALTE
IPC: A61K49/00
Filed: 2008-09-12
Abstract: Disclosed is a nanoparticular formulation comprising 1) a compound comprising polyethylene glycol (PEG) or methoxypolyethylene glycol as hydrophilic structural element and an alkyl chain as lipophilic structural element and 2) a near fluorescent dye which is indocyanine green, wherein the alkyl chain has 3 to 30 carbon atoms, which can be independently mono- or poly-substituted with C1-C3 alkyl, hydroxyl or phenyl, wherein the hydrophilic and lipophilic structural element are connected via a covalent bond,and and wherein the nanoparticular formulation forms micelles in aqueous media. A process for preparing the formulation is also disclosed.
Patent NZ-587113-A (NZ)
Title: Heated tube for respiratory apparatus, with monitoring and control of temperature of tube
Inventor: BATH ANDREW RODERICK
IPC: A61M16/08
Filed: 2010-07-30
Abstract: A control system for a heated conduit for use in a respiratory apparatus has the following: a power supply to provide power to the heated circuit; an over-temperature control circuit to prevent overheating of the heated conduit; a heating control circuit configured to control heating to obtain a predetermined temperature; a sensing circuit including a sensing resistor configured to indicate the temperature of a sensor in the heated conduit; and a bias generator configured to provide a first source voltage to the sensing circuit so that the temperature of the heated conduit is continuously monitored.
Patent NZ-592010-A (NZ)
Title: Systemic treatment of blood-sucking and blood-consuming parasites by oral administration of a parasiticidal agent
Inventor: JOHNSON ROLAND H
IPC: A61K31/44
Filed: 2009-09-30
Abstract: Disclosed herein is a pharmaceutically acceptable composition of a parasiticidally effective, subtoxic amount of imidacloprid when used for oral delivery to non-human mammals to control blood-sucking or consuming parasites thereon, wherein the imidacloprid is the only parasiticidal agent present in the pharmaceutical composition, and wherein the composition provides imidacloprid in a single dose level of 0.01 mg/kg to 30 mg/kg. Also disclosed is the use of a parasiticidally effective, subtoxic amount of imidacloprid for the manufacture of a medicament for the control of blood-sucking or consuming parasites on a mammal, wherein the imidacloprid is the only parasiticidal agent present in the medicament and wherein the medicament provides imidacloprid in a single dose level of 0.01 mg/kg to 30 mg/kg.
Patent NZ-593240-A (NZ)
Title: Random homozygous gene perturbation (rhgp) with thermal assymetric interlaced (tail)-pcr
Inventor: KINCH MICHAEL S
IPC: C12Q1/70
Filed: 2010-01-06
Abstract: 593240 Disclosed is an in vitro method of identifying targets for development of therapeutic drugs to address a disease condition, comprising: Transducing a population of mammalian cells expressing an activation factor, said cells comprising a host genome, with viral particles comprising a gene search vector comprising an inducible promoter which is inactivated in the absence of an inducing agent, wherein said gene search vector inserts into said host genome at a host gene, in a sense or opposite orientation to the host gene and generates a sense or antisense RNA in the presence of said inducing agent, whereby expression of said host gene is either suppressed at both alleles or enhanced by said insertion, wherein a sufficient number of insertion events occur in said population to ensure insertion of said gene search vector in substantially all genetic loci of said genome; Inspecting the transduced population of mammalian cells to identify cells exhibiting a phenotype unique to said disease condition; Identifying each genetic sequence at the point of insertion of said gene search vector (GSV) in those cells exhibiting a phenotype unique to said disease condition; and Characterising each said genetic sequence at the point of insertion of GSV to determine whether perturbation of said genome by said insertion has caused over expression or reduced expression of said genetic sequence, wherein said sequences are identified as targets for development of therapeutic drugs to address said disease condition.
Patent NZ-598629-A (NZ)
Title: Recessed wall-mounted outlet box with push-pull handle assembly
Inventor: HENNINGSEN MARSHALL W
IPC: E03C1/02
Filed: 2012-03-07
Abstract: 598629 An outlet box for controlling a flow of water from a supply line to an outlet line, comprising a housing 22 configured for mounting in a support wall, the housing 22 having an open front permitting access to an interior portion of the housing 22, a stop valve 44 having a valve handle 60 that is operable to selectively open and close the stop valve 44, a valve inlet shank 50 that is releasably attachable to the supply line, and at least one outlet 56 attachable to the outlet line, the stop valve 44 being replaceable from inside the housing 22 after mounting the housing 22 in the support wall, at least one retaining member disposed inside the housing 22 to maintain the stop valve 44 and valve inlet shank 50 in a desired positional relationship to the housing 22 and to prevent the valve inlet shank 50 from slipping through an opening in the housing 22 during installation or replacement of the stop valve 44, a control rod 48 having a distal end linked to a handle portion of the stop valve 44 and a proximal end attached to a control knob 30, and a faceplate substantially covering the open front of the housing 22, the faceplate being releasably attachable to the housing 22, and having at least one opening configured to permit the passage of the control rod 48 and the outlet line through the at least one opening, the control rod 48 being axially movable by the application of an axially directed force to the control knob 30 from a first position where the stop valve 44 is open and fluid communication is established between the supply line and the outlet line to a second position where the stop valve 44 is closed and fluid communication between the supply line and the outlet line is blocked.
Patent NZ-600289-A (NZ)
Title: Composition suitable for production of foam extinguishants
Inventor: STEINBRENNER ULRICH
IPC: A62D1/00
Filed: 2010-10-29
Abstract: The disclosure relates to compositions for foam extinguishants which do not comprise any organofluorine compounds and nevertheless meet the highest demands on the extinguishing properties. The compositions comprise at least one fatty alcohol, at least one thickener and at least one acrylic polymer, but the composition does not comprise any organohalogen compounds, more particularly any organofluorine compounds. The present disclosure also relates to the use of such a composition for production of a foam extinguishant and to the use of the composition for fighting fires, especially for fighting fires of organic liquids, known as liquid fires.
Patent NZ-601144-A (NZ)
Title: Heavy load trailer
Inventor: BARRY RUSSELL
IPC: B62D12/02
Filed: 2010-12-08
Abstract: 601144 A heavy load trailer (100) suitable for attachment to a prime mover is disclosed. The trailer includes a front steerable self-tracking axle (115), rear steerable self-tracking axle (120) and a non-steerable axle set (125) positioned between the front and rear axles. A frame (110) is supported by the front, rear and non-steerable axles. The self-tracking axles advantageously provide improved manoeuvrability and reduce damage to road infrastructure as they produce less scuffing on road surfaces.
Patent NZ-619528-A (NZ)
Title: Vertical take-off and landing aircraft
Inventor: TSUNEKAWA MASAYOSHI
IPC: B64C29/00
Filed: 2012-06-29
Abstract: A vertical take-off and landing aircraft (1) is disclosed. The aircraft comprises: a propulsion mechanism (2), an engine (3), a frame, seating (5), a control stick (6), and a landing undercarriage (7). The propulsion mechanism (2) includes a fan (21) to generate lift and thrust. The engine (3) provides motive power to the propulsion mechanism (2). A frame couples the propulsion mechanism (2) and the engine (3) where seating (5) is connected to and suspended from the frame so as to be swingable back and forth relative to the frame. The control stick (6) is connected to the frame and a landing undercarriage (7) is connected to the frame or the seating (5). The propulsion mechanism (2) is connected to the frame such that a drive shaft of the fan is directed vertically during landing, and the frame is moved relative to the seating (5) by manipulating the control stick (6) to change orientation of the propulsion mechanism (2).
Patent NZ-620339-A (NZ)
Title: N-hetero-ring-substituted amide derivative
Inventor: YOSHITOMI TOMOMI
IPC: C07D413/12
Filed: 2012-07-27
Abstract: Provided are N-hetero-ring-substituted amide oxadiazole derivative compounds of the general formula (I), wherein the variables are as defined in the specification. Examples of the compounds include 4-(5-{ (1R)-1-[4-(cyclopropylcarbonyl)phenoxy]propyl} -1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S,4R)-4-hydroxytetrahydrofuran-3-yl]benzamide and 4-(S-{ (1R)-1-[4-(cyclopropylcarbonyl)phenoxy]ethyl} -1,2,4-oxadiazol-3-yl)-2-fluoro-N-[(3S)-2-oxopyrrolidin-3-yl]benzamide. The compounds may be useful in the treatment of diabetes and obesity.
Patent NZ-623838-A (NZ)
Title: Pharmaceutical compositions for the treatment of diabetes mellitus
Inventor: TAKAHASHI TEISUKE
IPC: C07D335/02
Filed: 2010-04-16
Abstract: Disclosed is a pharmaceutical composition comprising a combination of (A) (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (Luseogliflozin / TS-071) or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt; and (B) an insulin sensitizer, selected from rosiglitazone or pioglitazone. Also disclosed is the use of a combination of: (A) Luseogliflozin or a pharmaceutically acceptable salt thereof or a hydrate of the compound or the salt; and (B) an insulin sensitizer, selected from rosiglitazone or pioglitazone; in the manufacture of a medicament for preventing or treating diabetes mellitus, diseases associated with diabetes mellitus, or complications of diabetes mellitus (such as diabetic retinopathy, diabetic nephropathy, diabetic neuropathy, cerebrovascular disorder, ischemic cardiac disease, or peripheral arterial disease), wherein (A) and (B) are formulated for simultaneous or separate administration.
Patent NZ-625359-A (NZ)
Title: Fluid temperature modification apparatus
Inventor: KULARATNA ALYTHWELA DOMINGO VITHANAGE NIHAL
IPC: H05B1/00
Filed: 2013-05-21
Abstract: A fluid temperature modification apparatus for heating fluid in a conduit is disclosed. The apparatus comprises at least one temperature modification element being located adjacent to an outlet of the conduit. At least one energy storage capacitor and at least one trigger switch. The switch connects the capacitor to the temperature modification element.
Patent NZ-627341-A (NZ)
Title: Sliding door or window latch
Inventor: STUART HORWOOD
IPC: E05B65/08
Filed: 2013-07-18
Abstract: А sliding door or window latch (1) is disclosed including а strike (3) and a latch body (2). The strike has a latch engagement feature (13) an anti-lift feature and an anti-slam mechanism contact surface (41). The latch body (2) includes a housing, а latch member (6) and а protrusion (33) that extends from the latch housing. The protrusion (33) is movable between а fully extended position and а partially extended position and an anti-slam mechanism is actuated by the protrusion (33). The anti-slam mechanism restricts motion of the latch (6) the unlatched position. In use, when а sliding door or window is moved to а closed position the protrusion moves to the partially extended position (Fig. 5), to actuating the anti-slam mechanism and also prevents vertical movement of the latch body relative to the strike.
Patent NZ-703148-A (NZ)
Title: Modified factor x polypeptides and uses thereof
Inventor: MADISON EDWIN L
IPC: C07K14/745
Filed: 2013-03-15
Abstract: Modified Factor X (FX) polypeptides, including Factor X zymogen, Factor Xa and other forms of Factor X, that contain the amino acid replacement serine or threonine at the residue corresponding to valine at position196 (V17 by chymotrypsin numbering) are provided. The modified FX polypeptides, when in active form, exhibit increased co-factor dependence. By virtue of this increase, the modified FX polypeptides are substantially inactive in the absence of co-factor, and, thus, are useful for treating coagulation disorders. The FX polypeptides optionally contain one or more additional amino acid replacements that confer other advantageous properties.
Patent NZ-703940-A (NZ)
Title: Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
Inventor: CAPONIGRO GIORDANO
IPC: A61P35/00
Filed: 2013-08-05
Abstract: The present invention provides a pharmaceutical combination comprising (a) a B-Raf inhibitor which is Compound A or a pharmaceutically acceptable salt thereof, (b) an EGFR inhibitor, wherein the EGFR inhibitor is cetuximab or erlotinib and, optionally, (c) a PI3K-α inhibitor, wherein the PI3K-α inhibitor is Compound B or a pharmaceutically acceptable salt thereof, wherein the combination is adapted for simultaneous, separate or sequential administration. The present invention also provides the uses of such combination in the treatment of proliferative diseases and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
Patent NZ-707260-A (NZ)
Title: Oxygen concentrator systems and methods
Inventor: WILKINSON WILLIAM R
IPC: A61M16/10
Filed: 2013-10-14
Abstract: When an oxygen concentrator, is not being used (for example, when the unit is turned off, being shipped, stored, or the like), the gas separation adsorbent may be detrimentally affected and/or deactivated, and thus, the life of the device (gas separation adsorbent) may be affected. In order to at least partially mitigate this issue, a method and an apparatus capable of performing said method are provided. The method includes the steps of assessing the pressure of at least one canister of the oxygen concentrator while the oxygen concentrator is in an off state and subsequently enabling the compressor at a speed sufficient to pressurise the canister to a predetermined pressure based on the assessed pressure of the oxygen when the oxygen concentrator is in an off state.
Patent NZ-707773-A (NZ)
Title: Methods of treating liver diseases
Inventor: HUGHES THOMAS
IPC: A61P3/06
Filed: 2013-11-05
Abstract: The invention provides tricyclic compounds and their use in the manufacture of medicaments for the treatment or prevention of liver fibrosis. The invention relates to a specific compound represented by Formula IV.
Patent NZ-721864-A (NZ)
Title: Ultrafiltration unit for continuous buffer or media exchange from a protein solution
Inventor: SCHWAN PETER
IPC: A61K35/14
Filed: 2015-02-13
Abstract: Method for continuous ultrafiltration of a feed stream containing biopharmaceutical products in a unit for continuous ultrafiltration, wherein the feed stream is washed with a washing fluid via at least one capillary ultrafiltration membrane of a capillary ultrafiltration module, wherein the feed stream is conveyed into the capillary and the washing fluid is conveyed over the outside of the capillary, wherein the feed stream and the washing fluid are continuously fed into the ultrafiltration module, and is continuously removed from the ultrafiltration module, wherein the feed stream and the washing fluid is not circulated into the ultrafiltration module and the removal of a product stream comprising a retentate is regulated such that no undesired net flows can pass from the capillary interior to the capillary exterior or vice versa, and wherein the capillary ultrafiltration module is bubble free on both a feed side and a jacket side via a priming procedure in which both the feed side and the jacket side are flushed with buffer solution until no more gas bubbles escape from the ultrafiltration module, and wherein both the feed side and the jacket side are flushed by the buffer solution at a flow rate ranging between 10% and 100% of a blood flow rate. The invention provides a solution which enables adjustment of the product stream, in particular adjustment of the concentration, pH and/or conductivity of a continuous product stream by buffer exchange.
Patent NZ-725344-A (NZ)
Title: System and method for determining sleep stage
Inventor: HENEGHAN CONOR
IPC: G06F17/14
Filed: 2013-09-19
Abstract: Disclosed is a method for classifying sleep stages of a subject. A processor selects one of a plurality of signals to process relating to bodily movement or respiration movements of the subject. A wavelet transform is performed on the selected signal from which a mask is generated. Features are then extracted from the transformed signal in accordance with the mask and a sleep stage is classified based on the extracted features.
Patent NZ-726792-A (NZ)
Title: Compositions and methods to treating hemoglobinopathies
Inventor: MILSOM MICHAEL
IPC: A61K48/00
Filed: 2015-04-24
Abstract: Embodiment herein provide specially designed synthetic BCL11A-targeting microRNAs for RNA polymerase II expression, and methods o use to treat hemoglobinopathies such as sickle cell disease or thalassemia by increasing the expression levels of fetal hemoglobin levels. In particular illustrative embodiment, the present invention provides, in part, improved compositions and methods for achieving gene therapy in hematopoietic cells and hematopoietic precursor cells, including erythrocytes, erythroid progenitors, and embryonic stem cells. The invention further provides improved gene therapy methods for treating hematoppictic-related disorders.
Patent NZ-744819-A (NZ)
Title: Teat opening protection patch for livestock
Inventor: INUI YOJI
IPC: A01K13/00
Filed: 2017-02-16
Abstract: This invention relates to a teat opening protection patch and method of protecting a teat opening of livestock, the patch being stuck to the teats so as to cover the teat openings for an extended period of time to protect the teats from mastitis causing bacteria. The patch is stuck to portions inclusive of the teat openings of livestock, and includes a laminate 1 of an elastic sheet 2 and an adhesive layer 3 laminated on one surface of the elastic sheet 2, the laminate 1 having a double-stretched tensile stress in a range of 0.1 to 5 N. The method comprises sticking the surface of the teat opening protection patch on the side of the adhesive layer 3 to the teat so as to cover the teat opening of the livestock.
Patent NZ-745979-A (NZ)
Title: Small-size reduction gearbox
Inventor: WANG TING
IPC: F16H57/029
Filed: 2018-09-03
Abstract: An objective of the present invention is to provide a small-size reduction gearbox, which has a smaller size and reliable sealing without oil leakage. A small-size reduction gearbox is provided, comprising an involute gear and a driven gear assembly linked with the involute gear; the involute gear at least consists of a first fixation segment, an engagement segment, a transition segment and a second fixation segment, the engagement segment is located between the transition segment and the first fixation segment, the transition segment is located between the second fixation segment and the engagement segment, and the involute gear is processed by hobbing to obtain the engagement segment and the transition segment; the first fixation segment is fixed to a box body via a first bearing, a bushing is fixedly sheathed on the involute gear, the bushing consists of a first bushing portion and a second bushing portion, the first bushing portion has an outer diameter greater than that of the second bushing portion, the first bushing portion is sheathed on the transition segment and the second bushing portion is sheathed on the second fixation segment, and a second bearing is sheathed on the second bushing portion.